Our legal, medical, and technical policy experts have collected examples where pharmaceutical companies are suspected of using their monopolies to charge excessive prices for their medicines. We investigate these and, if evidence of malfeasance is found, may bring a case.
Other Cases of Interest:
- mexiletine (Namuscla, message in Dutch only)
- pyrimethamine (Daraprim)
- lithium (Priadel)
We investigate practices around the accessibility and availability of medicines, and call pharmaceutical companies to account if these are unacceptable. If necessary, we take legal action. But we cannot do this alone – please support us!